Pharma Mar : Q2 2021 results affected by the absence of upfront/milestone payments this year, but with numbers above expectations
>Sales beat our estimates due to the higher Zepzelca sales - Total revenues improved +20% y-o-y to € 31m, 19% above our expectations, with Biopharma sales up +22% thanks to the sales of Zepzelca in Europe under the temporary use authorisation program. The diagnostic division registered a 66% drop in the quarter due to pricing competition for the COVID tests which improved results above the normal levels in the same period last year. EBITDA reached € 20m (8% above...
Oddo Securities provides securities brokerage and research services. The company offers equity, economic, and derivatives research and credit analysis services. It focuses on insurance, automotive, building materials, pharmaceuticals, telecommunications, information technology, and agri-food industries.
Unfortunately, this report is not available for the investor type or country you selected.
Browse all ResearchPool reportsReport is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.